Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
2021-01-07 22:09:27BobLietal
四川生理科學(xué)雜志 2021年7期
Bob T Li,et al.
Trastuzumab deruxtecan showed durable anticancer activity in patients with previously treated HER2-mutant NSCLC.The safety profile included interstitial lung disease that was fatal in two cases.
